AUR-AD9I-TTM3-A-1-1-R-A542-39
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.560
- OXIDATIVE_PHOSPHORYLATION+0.540
- FATTY_ACID_METABOLISM+0.520
- BILE_ACID_METABOLISM+0.490
- COAGULATION+0.480
- PEROXISOME+0.460
- MYC_TARGETS_V2+0.430
- ADIPOGENESIS+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
- PROTEIN_SECRETION+0.350
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- INTERFERON_ALPHA_RESPONSE-0.330
- ALLOGRAFT_REJECTION-0.320
- HEDGEHOG_SIGNALING-0.320
- INFLAMMATORY_RESPONSE-0.250
- NOTCH_SIGNALING-0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- G2M_CHECKPOINT-0.240
- KRAS_SIGNALING_UP-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AD9F-TTM3-A-1-1-R-A542-39 | — | C | 0.852 |
| 2 | TCGA-E2-A14O-01A-31R-A115-07 | — | B | 0.852 |
| 3 | TCGA-A8-A07P-01A-11R-A00Z-07 | — | B | 0.824 |
| 4 | SRR6013510 | — | cohortA4 | 0.796 |
| 5 | TCGA-E2-A1LB-01A-11R-A144-07 | — | F | 0.794 |
| 6 | bf93be3e-d4f1-4efb-9841-ca8ad81b237e | — | — | 0.788 |
| 7 | SRR1516101 | — | — | 0.787 |
| 8 | AUR-AD9F-TTM1-A-1-1-R-A542-39 | — | C | 0.785 |
| 9 | SRR13311171 | — | — | 0.779 |
| 10 | C3N-01024 | — | cohortA1 | 0.776 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.560 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.520 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.490 | Inavolisib | — uncovered |
| COAGULATION | 0.480 | Binimetinib | — uncovered |
| PEROXISOME | 0.460 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.420 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |